According to the registration rules, immunotherapy could be administered either in monotherapy or in combination with chemotherapy, based on the percentage of tumor cells (tumor proportion score, TPS) and/or immune cells with PD-L1 expression (combined proportion score, CPS), which is determined by IHC during qualification for the treatment. Here, CD274 is linked to neoplasm.